NunaBio

Executive Summary

NunaBio is a next-generation contract development and manufacturing organization (CDMO) specializing in cell-free DNA synthesis and production. Founded in 2021 and headquartered in London, UK, the company leverages the programmability and biocompatibility of DNA to serve a broad range of applications, including therapeutics, diagnostics, and advanced materials. By offering universal, cell-free DNA solutions in any format, NunaBio aims to overcome the limitations of traditional cell-based DNA manufacturing, such as scalability, purity, and speed. The company's approach positions it as a key enabler in the synthetic biology and biologics sectors, with potential to accelerate the development of gene therapies, mRNA vaccines, and DNA-based data storage. While still in its early stages, NunaBio's innovative cell-free platform could disrupt the DNA manufacturing landscape and capture value across multiple high-growth markets.

Upcoming Catalysts (preview)

• Q3 2026First Major Commercial Partnership or Licensing Deal60% success
• H2 2026Series A Funding Announcement70% success
• Q4 2026Publication of Proof-of-Concept Data in High-Impact Journal50% success